Table 3.

Reported progression-free survival and response rates from PARAMOUNT trial.

	Pemetrexed + BSC (N = 359)	Placebo + BSC (N = 180)
PFS (months)	3.9 (3.0–4.2)	2.6 (2.2–2.9)
Response rates n (%)*	9 (2.9)	0 (0.6)

Note:

^*Response rates after randomization.